| 摘要 |
Provided is an agent for treating/improving female hormone-dependent proliferative diseases containing a low-molecular peptide, especially an erythropoietin mimetic peptide (EMP), in particular EMP9, having an erythropoietin receptor antagonizing action. EMP9 is administered intravenously or directly to the focus of adenomyosis, endometriosis, uterine fibroids, or benign prostatic hypertrophy proliferative organ disease, which are female hormone-dependent diseases, and these diseases can be improved or treated. |
